Lopinavir/Ritonavir Viatris is used in combination with other medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV\-1\), a virus that causes acquired immune deficiency syndrome (AIDS). Lopinavir/Ritonavir Viatris contains the active substances lopinavir and ritonavir. Lopinavir/Ritonavir Viatris is a ‘generic medicine’. This means that it contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Lopinavir/Ritonavir Viatris is Kaletra.
Therapeutic Indication
Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV\-1\) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV\-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Therapeutic Area (MeSH)
ATC Code
J05AR10
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
EMA Name
Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Medicine Name
Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Aliases
N/ANo risk management plan link.
